Supporting the Patient with Chronic Hepatitis During Treatment

  • Nezam H. Afdhal
  • Tiffany Geahigan
Part of the Clinical Gastroenterology book series (CG)


Successfully managing the patient with chronic hepatitis C (CHC) can be a challenge to the physician. Not only does the patient with CHC impose a specific problem with therapy, but in addition the therapy itself is complex, and is associated with a multitude of side effects. This chapter examines strategies for the management of side effects in patients treated with both interferon (IFN) and IFN—ribavirin combination therapy. In the clinical trial scenario, approx 90% of patients can complete 6 mo of therapy with IFN and ribavirin, and 80% can complete a full 48 wk course of treatment (1,2). This excellent level of compliance should be achievable in the office setting. Understanding and recognizing the side effects associated with IFN—ribavirin therapy will help the clinician in educating the patient and family about the optimal strategies for successful therapy of CHC. Although this chapter focuses predominantly on IFN-based therapy, it also briefly discusses some of the newer treatments for hepatitis C virus (HCV), including pegylated IFNs.


Chronic Hepatitis Lichen Planus Alopecia Areata Interferon Alfa Porphyria Cutanea Tarda 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–1492.PubMedCrossRefGoogle Scholar
  2. 2.
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–1432.PubMedCrossRefGoogle Scholar
  3. 3.
    Afdhal NH, Keaveny AP, Nunes DP. Hepatitis C treatment of patients in an urban medical center. Hepatology 2000; 32: 565A 4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.CrossRefGoogle Scholar
  4. 5.
    Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993; 153: 2025–2030.PubMedCrossRefGoogle Scholar
  5. 6.
    Taruschio G, Santarini F, Sica G, et al. Psychiatric disorders in hepatitis C virus related chronic liver disease (abstract). Gastroenterology 1996; 110: A1342.Google Scholar
  6. 7.
    Hunt CM, Dominitz JA, Bute BP, et al. Effect of interferon-a treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482–2486.PubMedCrossRefGoogle Scholar
  7. 8.
    Lee DH, Jamal H, Regenstein FG, et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42: 186–191.PubMedCrossRefGoogle Scholar
  8. 9.
    Singh N, Gayowski T, Wagener NM, et al. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67: 69–72.PubMedCrossRefGoogle Scholar
  9. 10.
    Austin GE, Jensen B, Leete J, et al. Prevalence of hepatitis C virus seropositivity among hospitalized veterans. Am J Med Sci 2000; 319: 353–359.PubMedCrossRefGoogle Scholar
  10. 11.
    Younossi ZM, Guyatt G. Quality-of-life assessments and chronic liver disease. Am J Gastroenterol 1998; 93: 1037–1041.PubMedCrossRefGoogle Scholar
  11. 12.
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–212.PubMedCrossRefGoogle Scholar
  12. 13.
    Bonkovsky HL, Wooley JM, the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264–270.PubMedCrossRefGoogle Scholar
  13. 14.
    Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. Hepatology 1999; 29: 277–279.PubMedCrossRefGoogle Scholar
  14. 15.
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(Suppl 1): 112S–121S.CrossRefGoogle Scholar
  15. 16.
    Maddrey WC. Safety of combination interferon alpha-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19(Suppl 1): 67–75.PubMedGoogle Scholar
  16. 17.
    Kingsley D. Interferon alfa for chronic hepatitis C infection. Lancet 1999; 353–499.Google Scholar
  17. 18.
    Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–243.Google Scholar
  18. 19.
    Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–291.PubMedCrossRefGoogle Scholar
  19. 20.
    Rebetron Package Insert. Schering Plough, Kenillworth, NJ.Google Scholar
  20. 21.
    Barkhuizen A, Rosen HR, Wolf S, et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C. Am J Gastroenterol 1999; 94: 1355–1360.PubMedGoogle Scholar
  21. 22.
    Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91: 309–313.PubMedGoogle Scholar
  22. 23.
    Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27: 1421–1427.PubMedCrossRefGoogle Scholar
  23. 24.
    Kuga K, Hasumura S, Nagamori S, et al. Intraocular hemorrhage developing during interferon therapy. Intern Med 1996; 35: 15–18.PubMedCrossRefGoogle Scholar
  24. 25.
    Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival heamorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79: 150–152.PubMedCrossRefGoogle Scholar
  25. 26.
    Manesis EK, Petrou C, Brouzas D, et al. Optic tract neuropathy complicating lowdose interferon treatment. J Hepatol 1994; 21: 474–477.PubMedCrossRefGoogle Scholar
  26. 27.
    Fortin E. Neurovisual complications of interferon-α therapy. Hepatology 1998; 27: 1441–1442.PubMedCrossRefGoogle Scholar
  27. 28.
    Daoud MZ, Gibson LE, Daoud S, et al. Chronic hepatitis C and skin diseases. Mayo Clin Proc 1995; 70: 559–564.PubMedCrossRefGoogle Scholar
  28. 29.
    Stryjek-Kaminska D, Olchsendorf F, Roder C, et al. Photoallergic skin reaction to ribavirin. Am J Gastroenterol 1999; 94: 1686–1688.PubMedCrossRefGoogle Scholar
  29. 30.
    Kernland KH, Hunziker TH. Alopecia areata induced by interferon alpha? Dermatology 1999; 198: 418–419.PubMedGoogle Scholar
  30. 31.
    Lisker-Melman M, DiBisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 120: 2155–2160.Google Scholar
  31. 32.
    Watanabe U, Hashimoto E, Hisamitsu T, et al. Risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399–403.PubMedGoogle Scholar
  32. 33.
    Preziati D, LaRosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587–593.PubMedCrossRefGoogle Scholar
  33. 34.
    GisslingerH, Gilly B, Woloszczuk W, etal. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363–367.Google Scholar
  34. 35.
    Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-a. 1998; Semin Oncol 25(Suppl 1): 54–63.PubMedGoogle Scholar
  35. 36.
    Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy of malignant carcinoid tumors. Ann Intern Med 1991; 115: 178–183.PubMedGoogle Scholar
  36. 37.
    Koizumi S, Mashio Y, Mizuto H, et al. Graves’ hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. Intern Med 1995; 34: 58–60.PubMedCrossRefGoogle Scholar
  37. 38.
    Caronia S, Taylor K, Luigi P, et al. Further evidence for an association between nonInsulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059–1063.PubMedCrossRefGoogle Scholar
  38. 39.
    Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328–333.PubMedCrossRefGoogle Scholar
  39. 40.
    Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato-Gastroenterology 1998; 45: 1748–1751.PubMedGoogle Scholar
  40. 41.
    Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424–1429.PubMedCrossRefGoogle Scholar
  41. 42.
    Martin TG, Shuman MA. Interferon-induced thrombocytopenia: is it time for thrombopoietin? Hepatology 1998; 28: 1430–1432.PubMedCrossRefGoogle Scholar
  42. 43.
    Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa and depression. Hepatology 2000; 31: 1207–1209.PubMedCrossRefGoogle Scholar
  43. 44.
    Gleason O, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510–512.PubMedCrossRefGoogle Scholar
  44. 45.
    Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferona. Am J Gastroenterol 1993; 88: 760–761.PubMedGoogle Scholar
  45. 46.
    Brown RR, Ozaki Y, Datta SP, et al. Implications of interferon-induced trytophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 1991; 294: 425–435.PubMedCrossRefGoogle Scholar
  46. 47.
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–881.PubMedGoogle Scholar
  47. 48.
    Lau DTY, Kleiner DE, Chany MG, et al. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–1127.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Nezam H. Afdhal
  • Tiffany Geahigan

There are no affiliations available

Personalised recommendations